SCHEMBL13667641

SCHEMBL13667641

CCC(C)(C)NC(=S)NC(=O)Cc1ccccc1F

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.52
NPSR1 Q6W5P4 1/20 0.46
KDM4E B2RXH2 2/20 0.45
PPIA P62937 1/20 0.44
ALDH1A1 P00352 2/20 0.43
ANO1 Q5XXA6 1/20 0.43
LMNA P02545 3/20 0.42
RAB9A P51151 2/20 0.42
HPGD P15428 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
GAA P10253 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
VNN1 O95497 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13607973 0.88 ANO1 (0.51) RIPK1NPSR1KDM4EPPIAALDH1A1
SCHEMBL2605729 0.83 RIPK1 (0.50) RIPK1NPSR1KDM4EPPIAALDH1A1
SCHEMBL171506 0.80 PPIA (0.50) NPSR1KDM4EPPIAALDH1A1LMNA
SCHEMBL14019877 0.77 PPIA (0.57) RIPK1NPSR1KDM4EPPIAALDH1A1
SCHEMBL13619757 0.77 KDM4E (0.52) RIPK1KDM4EALDH1A1ANO1LMNA
SCHEMBL13926143 0.77 ALDH1A1 (0.56) NPSR1PPIAALDH1A1LMNARAB9A
SCHEMBL171354 0.74 MAPK8 (0.52) PPIAALDH1A1LMNARAB9AHPGD
SCHEMBL14019880 0.72 ANO1 (0.50) NPSR1KDM4EALDH1A1ANO1LMNA
SCHEMBL14019928 0.72 EPHX1 (0.51) ALDH1A1ANO1LMNARAB9AHPGD
SCHEMBL14019870 0.72 EPHX1 (0.51) ALDH1A1ANO1LMNARAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264440-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET RIPK1 614/4885NPSR1 1765/4885KDM4E 2282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.